Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
- PMID: 29930761
- PMCID: PMC6007462
- DOI: 10.18632/oncotarget.25519
Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
Abstract
Apoptosis induction has emerged as a treatment option for anticancer therapy. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmembrane protein, is a potent and specific pro-apoptotic protein ligand, which activates the extrinsic apoptosis pathway of the cell death receptors. Here we describe the construction and characterization of a new soluble TRAIL, sfTRAIL, stabilized with the trimerization Foldon domain from the Fibritin protein of the bacteriophage T4. Supernatants of 0.22 μM-filtered supernatants were produced in Vero-transduced cells with HSV1-derived viral amplicon vectors. Experiments were undertaken in two known TRAIL-sensitive (U373 and MDA.MB.231) and two TRAIL-resistant (MCF7 and A549) cell lines, to determine (i) whether the sfTRAIL protein is synthetized and, (ii) whether sfTRAIL could induce receptor-mediated apoptosis. Our results showed that sfTRAIL was able to induce apoptosis at concentrations as low as 1899.29 pg/mL (27.71 pM), independently of caspase-9 activation, and reduction in cell viability at 998.73 fM.
Keywords: TRAIL; amplicon vectors; apoptosis; cancer treatment.
Conflict of interest statement
CONFLICTS OF INTEREST Authors MEM and ALC have a patent for this technology.
Figures




Similar articles
-
Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.Cancer Res. 2000 Aug 1;60(15):4122-9. Cancer Res. 2000. PMID: 10945619
-
Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.Cancer Res. 2001 Feb 15;61(4):1645-51. Cancer Res. 2001. PMID: 11245478
-
Cancer gene therapy using a novel secretable trimeric TRAIL.Gene Ther. 2006 Feb;13(4):330-8. doi: 10.1038/sj.gt.3302658. Gene Ther. 2006. PMID: 16195699
-
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.Int J Cancer. 2002 Jun 1;99(4):491-504. doi: 10.1002/ijc.10376. Int J Cancer. 2002. PMID: 11992538
-
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.BMC Cancer. 2005 May 25;5:54. doi: 10.1186/1471-2407-5-54. BMC Cancer. 2005. PMID: 15916713 Free PMC article.
Cited by
-
Noncanonical Cell Death Induction by Reassortant Reovirus.J Virol. 2020 Oct 27;94(22):e01613-20. doi: 10.1128/JVI.01613-20. Print 2020 Oct 27. J Virol. 2020. PMID: 32847857 Free PMC article.
-
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.Int J Mol Sci. 2021 Jul 16;22(14):7628. doi: 10.3390/ijms22147628. Int J Mol Sci. 2021. PMID: 34299249 Free PMC article. Review.
-
Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation.Cancers (Basel). 2019 Jul 7;11(7):954. doi: 10.3390/cancers11070954. Cancers (Basel). 2019. PMID: 31284696 Free PMC article. Review.
References
-
- Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–8. https://doi.org/10.1038/35037722. - DOI - PubMed
-
- Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) J Clin Oncol. 2008;26:3621–30. https://doi.org/10.1200/JCO.2007.15.7198. - DOI - PubMed
-
- Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701–8. https://doi.org/10.1158/1078-0432.CCR-09-1692. - DOI - PubMed
-
- Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev. 2014;25:185–93. https://doi.org/10.1016/j.cytogfr.2013.12.009. - DOI - PubMed
-
- Hymowitz SG, O’Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry. 2000;39:633–40. https://doi.org/10.1021/bi992242l. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous